The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naive Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

被引：12

作者：

Passamonti, Francesco ^{[1
,2
]}

Foran, James M. ^{[3
,4
]}

Tandra, Anand ^{[5
]}

De Stefano, Valerio ^{[6
,7
]}

Fox, Maria Laura ^{[8
]}

Mattour, Ahmad H. ^{[9
]}

McMullin, Mary Frances ^{[10
]}

Perkins, Andrew Charles ^{[11
]}

Rodriguez-Macias, Gabriela ^{[12
]}

Sibai, Hassan ^{[13
]}

Qin, Qin ^{[14
]}

Sun, Yan ^{[14
]}

Potluri, Jalaja ^{[14
]}

Harb, Jason ^{[14
]}

How, Jonathan ^{[15
]}

机构：

[1] Univ Insubria, Univ Hosp Osped Circolo, Div Hematol, Varese, Italy

[2] Univ Insubria, Fdn Macchi ASST Sette Laghi, Varese, Italy

[3] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA

[4] Mayo Clin, Blood & Marrow Transplanat & Cellular Therapy, Jacksonville, FL 32224 USA

[5] Indiana Blood & Marrow Transplant, Indianapolis, IN USA

[6] Catholic Univ, Sect Hematol, Dept Radiol & Hematol Sci, Fdn Policlin A Gemelli, Rome, Italy

[7] Fdn Policlin Univ Agostino Gemelli IRCC, Rome, Italy

[8] Univ Hosp Vall dHebron Barcelona, Dept Hematol Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[9] Henry Ford Hosp, Detroit, MI 48202 USA

[10] Queens Univ, Ctr Med Educ, Belfast, Antrim, North Ireland

[11] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia

[12] Gregorio Maranon Gen Univ Hosp HGUGM, Dept Hematol, Madrid, Spain

[13] Univ Hlth Network, Div Med Oncol & Hematol, Leukemia Program, Princess Margaret Canc Ctr, Toronto, ON, Canada

[14] AbbVie Inc, N Chicago, IL USA

[15] McGill Univ, Montreal, PQ, Canada

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157949

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF). [J].

Mesa, Ruben A. ;

Kiladjian, Jean -Jacques ;

Catalano, John V. ;

Devos, Timothy ;

Egyed, Miklos ;

Hellman, Andrzei ;

McLornan, Donal ;

Shimoda, Kazuya ;

Winton, Elliott F. ;

Deng, Wei ;

Dubowy, Ronald L. ;

Maltzman, Julia D. ;

Cervantes, Francisco .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[22] MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis [J].

Mascarenhas, John ;

Kremyanskaya, Marina ;

Patriarca, Andrea ;

Palandri, Francesca ;

Devos, Timothy ;

Passamonti, Francesco ;

Rampal, Raajit K. ;

Mead, Adam J. ;

Hobbs, Gabriella ;

Scandura, Joseph M. ;

Talpaz, Moshe ;

Granacher, Nikki ;

Somervaille, Tim C. P. ;

Hoffman, Ronald ;

Wondergem, Marielle J. ;

Salama, Mohamed E. ;

Colak, Gozde ;

Cui, Jike ;

Kiladjian, Jean-Jacques ;

Vannucchi, Alessandro M. ;

Verstovsek, Srdan ;

Curto-Garcia, Natalia ;

Harrison, Claire ;

Gupta, Vikas .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (32) :4993-+

[23] POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naive Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib [J].

Vachhani, Pankit ;

Rampal, Raajit ;

Bradley, Terrence ;

Harrison, Claire ;

Jain, Tania ;

Kuykendall, Andrew T. ;

Palandri, Francesca ;

Mascarenhas, John O. ;

Al-Ali, Haifa Kathrin ;

Passamonti, Francesco ;

Nekhymchuk, Anna ;

Foss, Hilarie ;

Rothbaum, Wayne ;

Verstovsek, Srdan ;

Heidel, Florian .

BLOOD, 2024, 144 :18083-18084

[24] CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: Update of MANIFEST phase 2 study [J].

Platzbecker, U. ;

Mascarenhas, J. ;

Harrison, C. ;

Patriarca, A. ;

Devos, T. ;

Palandri, F. ;

Rampal, R. ;

Vannucchi, A. ;

Mead, A. ;

Kremyanskaya, M. ;

Somervaille, T. ;

Wondergem, M. ;

Hoffman, R. ;

Luptakova, K. ;

Wang, J. ;

Colak, G. ;

Shao, J. ;

Bobba, S. ;

Trojer, P. ;

Verstovsek, S. ;

Gupta, V .

ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 :158-158

[25] CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study [J].

Mead, Adam ;

Mascarenhas, John ;

Talpaz, Moshe ;

Patriarca, Andrea ;

Devos, Timothy ;

Palandri, Francesca ;

Passamonti, Francesco ;

Rampal, Raajit ;

Kremyanskaya, Marina ;

Scandura, Joseph ;

Somervaille, Tim ;

Wondergem, Marielle ;

Granacher, Nikki ;

Hoffman, Ronald ;

Gupta, Vikas ;

Luptakova, Katarina ;

Wang, Jing ;

Christo, Jessica ;

Colak, Gozde ;

Shao, James ;

Bobba, Suresh ;

Trojer, Patrick ;

Verstovsek, Srdan ;

Harrison, Claire .

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 :96-96

[26] Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naive Myelofibrosis Patients [J].

Harrison, Claire N. ;

Patriarca, Andrea ;

Mascarenhas, John ;

Kremyanskaya, Marina ;

Hoffman, Ronald ;

Schiller, Gary J. ;

Leber, Brian ;

Devos, Timothy ;

Kabir, Sujan ;

Senderowicz, Adrian ;

Mertz, Jennifer ;

Trojer, Patrick ;

Shao, James ;

Gupta, Vikas .

BLOOD, 2019, 134

[27] Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib [J].

Scandura, Joseph ;

Verstovsek, Srdan ;

Kremyanskaya, Marina ;

Talpaz, Moshe ;

Rampal, Raajit K. ;

Vannucchi, Alessandro ;

Gupta, Vikas ;

Palandri, Francesca ;

Patriarca, Andrea ;

Bose, Prithviraj ;

Chen, Dong ;

Zavidij, Oksana ;

Cui, Jike ;

Chang, Tzuu-Wang ;

Taverna, Pietro ;

Mascarenhas, John ;

Harrison, Claire .

BLOOD, 2022, 140 :1523-1525

[28] PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS RUXOLITINIB IN JAK INHIBITOR NAIVE PATIENTS WITH MYELOFIBROSIS: RESULTS OF THE SIMPLIFY-1 STUDY [J].

Gotlib, J. R. ;

Kiladjian, J-J. ;

Catalano, J. V. ;

Devos, T. ;

Egyed, M. ;

Hellman, A. ;

McLornan, D. P. ;

Shimoda, K. ;

Winton, E. F. ;

Deng, W. ;

Dubowy, R. L. ;

Maltzman, J. D. ;

Cervantes, F. ;

Mesa, R. A. .

HAEMATOLOGICA, 2017, 102 :320-320

[29] Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis [J].

Harrison, Claire N. ;

Gupta, Vikas K. ;

Gerds, Aaron T. ;

Rampal, Raajit ;

Verstovsek, Srdan ;

Talpaz, Moshe ;

Kiladjian, Jean-Jacques ;

Mesa, Ruben ;

Kuykendall, Andrew T. ;

Vannucchi, Alessandro M. ;

Palandri, Francesca ;

Grosicki, Sebastian ;

Devos, Timothy ;

Jourdan, Eric ;

Wondergem, Marielle J. ;

Al-Ali, Haifa Kathrin ;

Buxhofer-Ausch, Veronika ;

Alvarez-Larran, Alberto ;

Patriarca, Andrea ;

Kremyanskaya, Marina ;

Mead, Adam J. ;

Akhani, Sanjay ;

Sheikine, Yuri ;

Colak, Gozde ;

Mascarenhas, John .

FUTURE ONCOLOGY, 2022, 18 (27) :2987-2997

[30] Fedratinib: a pharmacotherapeutic option for JAK-inhibitor naive and exposed patients with myelofibrosis [J].

England, James T. ;

Gupta, Vikas .

EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (15) :1677-1686

← 1 2 3 4 5 →